3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
27
Lymphoma
22
Hematologic Diseases
20
Lymphoma, Large-Cell, Anaplastic
16
Lymphoma, Non-Hodgkin
11
Recurrence
5
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell
4
Lymphoma, T-Cell, Cutaneous
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Melanoma
2
Lymphoma, Primary Cutaneous Anaplastic Large Cell
2
Dendritic Cell Sarcoma, Interdigitating
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphomatoid Papulosis
1
Interventions
pembrolizumab
180
Cisplatin
44
Paclitaxel
41
Carboplatin
41
lenvatinib
31
Docetaxel
22
Pemetrexed
20
Fluorouracil
19
Capecitabine
16
Gemcitabine
15
Saline Solution
13
Oxaliplatin
13
Albumin-Bound Paclitaxel
10
epacadostat
9
130-nm albumin-bound paclitaxel
9
Leucovorin
8
Cetuximab
8
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
belzutifan
5
Dexamethasone
5
enzalutamide
4
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Brentuximab Vedotin
×
Clear all
NCT02684292
2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3
Completed
304 enrolled
1 FDA